IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
IDEAYA Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$33.81+0.96 (+2.92%)
Close on Oct 19, 2026
- Market cap
- $3.11B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-72.8%+108.1 pts over 5 years
Net margin
-52.0%+124.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3024.4% | +62.5% | +62.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -23.1% | -10.9% | |
| Return on assets | – | -16.8% | -10.2% | |
| Current ratio | – | 7.47 | 11.34 | |
| Capex to revenue | – | 2.5% | 1.1% | |
| Diluted shares | – | 25M | 88M |
Where the cash went
Fiscal 2021 to 2025, five years combined
IDEAYA Biosciences generated $576.86M from operations and spent $14.68M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$576.86M
Used
$14.68M
Capital expenditure$14.68M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-52.0%
×Asset turnover0.20×
×Equity multiplier1.07×
=Return on equity, FY2025-10.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -52.0% | 0.20× | 1.07× | -10.9% |
| FY2024 | -3921.1% | 0.01× | 1.06× | -32.7% |
| FY2023 | -483.0% | 0.05× | 1.07× | -23.3% |
| FY2022 | -115.2% | 0.13× | 1.18× | -18.0% |
| FY2021 | -178.1% | 0.08× | 1.36× | -19.9% |
| FY2020 | -176.6% | 0.10× | 1.38× | -23.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$113.70M
- Cash generatingOperating cash flow above zero-$71.10M
- Return on assets improvedROA up on the prior year-42.3% → -10.1%
- Earnings backed by cashOperating cash flow above net income-$71.10M vs -$113.70M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose14.97 → 11.34
- No dilutionShare count did not rise82M → 88M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.01 → 0.19